Guaifenesin

Quick links to important sections

Guaifenesin

Selected form

Treatment option: Cough

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Guaifenesin

Property Description
Active Ingredient Guaifenesin (Glyceryl guaiacolate)
Form Oral tablet (immediate- and extended-release), capsule, syrup, granules
Pharmacological Class Expectorant (a type of mucoactive agent)
General Purpose Loosening and thinning respiratory tract secretions
Origin Synthetic organic compound

Guaifenesin: Definition, Class, and Composition

Guaifenesin, formally identified as glyceryl guaiacolate, is a synthetic organic compound derived from guaiacol and serves as the active pharmaceutical ingredient in numerous respiratory products. It is primarily classified as an expectorant, a designation relating to its action on mucus properties. While available as a single-ingredient drug, Guaifenesin is frequently included in combination formulations alongside other agents like antitussives or decongestants, with the final product consisting of the active compound and standard pharmaceutical excipients or a liquid vehicle.


Available Forms and Oral Administration

Guaifenesin is an oral medication offered in a variety of dosage forms intended for ingestion. Patients find this ingredient in the form of a syrup (liquid solution), capsules, or various types of tablets. A key distinction is the presence of specialized extended-release variations, which are formulated to sustain the medication’s expectorant effect over a significantly longer period compared to standard immediate-release versions. This controlled release profile allows for less frequent dosing.


General Purpose of This Expectorant

As an expectorant, the general therapeutic purpose of Guaifenesin is to support the body in achieving a more productive cough by modifying airway secretions. Its primary action is to increase the volume and significantly reduce the viscosity (thickness) of the mucus and phlegm in the respiratory tract. This modulation of airway secretions enhances their clearance by promoting more effective expectoration. This mechanism facilitates the natural expulsion of mucus, thereby providing temporary relief from the subjective feeling of chest congestion associated with a wet or phlegmy cough.

Regulatory References

  1. PMC7006698
  2. PMC5724298

What side effects are possible with Guaifenesin?

Possible Side Effects and Safety Information

The official safety profile of Guaifenesin describes adverse reactions primarily affecting the gastrointestinal and nervous systems, classified according to standard regulatory frequency categories as documented in authoritative sources like the FDA and EMA. The information below reflects the adverse effects and high-level safety constraints as listed in official prescribing information.


Documented Adverse Reactions

The most Common adverse reactions officially documented are headache and disturbances to the gastrointestinal system, including nausea and vomiting

. Other effects, such as dizziness and some dermatological reactions (rash, hives), are also reported, but their frequency is often classified as Not Known (cannot be estimated from available data).


Serious Safety Concerns and Specific Constraints

While rare, the regulatory safety profile includes the potential for severe hypersensitivity reactions, such as angioedema (swelling of the face or throat) and severe skin reactions, which are recognized safety concerns.

Official labels address specific populations where caution may be needed, including use during pregnancy and lactation and in individuals with severe renal impairment or a history of acute porphyria. The medicine is also officially noted to have the potential to interfere with certain laboratory tests, specifically those that measure 5-HIAA and VMA, which may lead to falsely elevated results. Furthermore, regulatory guidelines advise that if a cough persists for more than seven days, medical reassessment is necessary.

Overdose and Emergency Response

Guaifenesin Overdose and when to seek help

Overdose Manifestations and Risk

Acute overdose of guaifenesin is generally classified as low-toxicity, though clinical signs may include nausea, vomiting, abdominal pain, and drowsiness. A risk of Central Nervous System (CNS) depression is officially documented in regulatory information but is only associated with extremely high doses. Furthermore, prolonged, excessive use has been associated with the potential for renal calculi (kidney stones). A critical official note for medical assessment is the drug's metabolite interference, which can falsely elevate levels of urinary 5-HIAA and cause color interference in the VMA test.

Emergency Actions and Supportive Management

Regulatory bodies mandate that prompt medical attention is critical for all individuals, including children, in a suspected overdose, even if no signs or symptoms are immediately noticeable. Individuals must get medical help or contact a Poison Control Center right away. Emergency services must be called if the person is unresponsive or experiencing severe symptoms such as trouble breathing or a seizure. Management is officially designated as symptomatic and supportive, as no specific antidote is known. For massive overdosage, supportive care may include gastric emptying and continuous observation.

Therapeutic Uses of Guaifenesin

Guaifenesin is generally used to help manage acute respiratory symptoms by addressing symptoms related to physical discomfort caused by secretions in the chest.

Symptomatic Relief and Secretion Management

Guaifenesin is commonly used for the symptomatic relief of chest congestion and the associated wet, productive cough that occur during acute illnesses. Indications include the common cold, flu, and acute bronchitis. The medication is applied to address symptom clusters characterized by thick and tenacious phlegm and mucus. By addressing the symptoms related to thick and tenacious phlegm, Guaifenesin may assist with easier clearance, contributing to improved comfort during periods of heightened symptoms.

“This supportive approach is relevant in contexts marked by increased discomfort or tension.”

This therapeutic approach is commonly used across various acute upper respiratory tract infections where significant mucus buildup is present. It is applied in addressing symptom clusters that create temporary functional strain, which supports patients during difficult episodes and assists with easing distress.


Quick Fact: Relief for Thick Mucus Guaifenesin may assist with easing the overall symptom load by addressing symptoms related to the difficulty of clearing accumulated phlegm, which is commonly used in contexts involving increased discomfort due to congestion.

Regulatory References

  1. NIH MedlinePlus overview of Guaifenesin uses

Eligibility and Restrictions for Use

Eligibility for Guaifenesin: Official Regulatory Status

Official regulatory documents define who is eligible to use guaifenesin, primarily based on age, hypersensitivity, and specific underlying health conditions.

Absolute Contraindications

Guaifenesin is contraindicated for patients with a known history of hypersensitivity or allergic reactions to the active substance or any other ingredients in the product formulation.

Age-Related Eligibility and Restrictions

Age Group Eligibility Status (Regulatory Labeling)
Adults and Adolescents (ge 12 years) Generally permitted for use.
Children 6 to 11 years Permitted for use, but dosage is lower than the adult dose.
Children under 12 years Prohibited from using extended-release tablet formulations.
Children under 4 years Use not recommended for over-the-counter (OTC) use due to safety concerns.

Conditional Use Populations

Specific populations are advised to use guaifenesin only under professional guidance, as stated in regulatory warnings:

  • Chronic Cough: Individuals with a persistent cough (e.g., associated with smoking, asthma, chronic bronchitis) or a cough producing an unusually large amount of phlegm are advised to consult a healthcare professional before self-medicating.
  • Organ Function: Patients with severe renal impairment or severe hepatic impairment are cautioned, as these conditions may affect the body's ability to clear the medicine.

Pregnancy and Lactation Eligibility

Guaifenesin is classified as FDA Pregnancy Category C, meaning risk cannot be ruled out. Its use during pregnancy is not generally recommended unless the potential benefit justifies the potential risk to the fetus. For lactating women, it is unknown if the substance is excreted into human milk, and use should be approached with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for single-ingredient Guaifenesin establishes a distinct interaction profile defined primarily by the risk of interference with specific diagnostic tests, rather than a wide range of drug-drug interactions.


Laboratory Test Interference

This is the most formally documented interaction in official labels. Guaifenesin or its metabolites can cause color interference with certain chemical reagents used in diagnostic assays. This effect may lead to false elevation of the results for specific urinary compound tests:

  • Vanillylmandelic Acid (VMA): Guaifenesin may falsely elevate urinary VMA levels, which are typically measured for the diagnosis of certain conditions.
  • 5-Hydroxyindoleacetic Acid (5-HIAA): The medicine may also cause false elevation of urinary 5-HIAA levels in some serotonin metabolite chemical tests.

As a constraint, official regulatory information indicates that Guaifenesin should be discontinued before the collection of a urine sample for these relevant diagnostic tests to ensure accurate results.


Absence of Documented Drug-Drug Interactions

The regulatory profile for single-ingredient Guaifenesin is further characterized by the absence of documented clinically significant interactions with other medicinal products. Official prescribing information does not list formal restrictions or mandatory administration timing rules for co-administration with other medications, nor does it specify interactions with food, alcohol, or herbal products that require official warnings or label modifications.

Mechanism of Action

Modulation via the Gastro-Pulmonary Vagal Reflex

This mechanism involves the drug acting as an irritant on vagal afferent receptors in the gastric mucosa, triggering a central response that modulates autonomic outflow to the respiratory glands. The resulting parasympathetic efferent signal causes an immediate increase in the volume and hydration of bronchial secretions.

Alteration of Mucus Viscoelasticity and Airway Secretion

Beyond the reflex, the circulating drug or its active components directly or indirectly influence respiratory epithelial cells, modulating the production of highly viscous mucin glycoproteins. This action reduces the stickiness and elasticity of the mucus layer; this change in rheology facilitates the thinning and mobilization of the secretions by the increased fluid volume.

Functional Modulation of Mucociliary Transport

The convergence of increased secretion hydration and reduced mucus viscosity promotes coupling between the cilia and the mucus blanket. This mechanistic outcome leads to a more rapid and effective mucociliary transport and the physiological process of expulsion of material from the lower airways.

Dosage and Administration Information

Guaifenesin is administered exclusively via the oral route, utilizing immediate-release (IR) or extended-release (ER) dosage forms, such as tablets, capsules, or syrups. The administration protocol focuses on specific dose, frequency, and form-specific handling.

Dosage and Frequency

Formulation Standard Dose (Adults ge 12 yrs) Frequency Max Daily Dose
Immediate-Release (IR) 200 mg to 400 mg Every 4 hours 2400 mg
Extended-Release (ER) 600 mg or 1200 mg Every 12 hours 2400 mg

Administration Conditions

Specific label instructions must be adhered to for proper administration. Every dose, regardless of the formulation, must be taken with a full glass of water. The medication can be administered with or without food. For extended-release tablets, the procedure requires that the tablet be swallowed whole and must not be crushed, broken, or chewed; this is essential for maintaining the controlled drug release. Furthermore, the use of extended-release formulations is not permitted for children under 12 years of age.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Guaifenesin


Evidence for Use in Acute Cough and Chest Congestion

Guaifenesin was evaluated in research exploring temporary, short-term patterns of cough and congestion symptoms that occur during common illnesses, such as the cold or flu. Research in this area primarily utilized short-term Randomized Controlled Trials (RCTs), where participants received either guaifenesin or an inactive placebo. These trials were applied in studies examining patient-reported experiences in contexts involving episodic or acute changes in symptoms.

Studies explored patient-reported outcomes describing perceived discomfort, such as daily scores for cough frequency and cough intensity. Researchers also monitored physiological strain, including measurements of sputum viscosity (thickness) and sputum volume. Findings were mixed, with some studies describing changes in cough and congestion scores, while others did not report clear differences when compared to placebo. Because the data for this indication are drawn from numerous separate short-term studies, evidence quality varies across studies, and research provides insight into short-term changes.

Evidence for Use in Stable Chronic Bronchitis

Research has also examined the extended-release formulation and its evaluation in patients with conditions presenting with cycles of stability and flare-ups, such as Stable Chronic Bronchitis. This research explores findings from a longer period of observation compared to the acute cough studies. These studies primarily utilized long-term observational studies that examined outcomes reflecting daily functioning or activity level, such as sustained changes in cough and sputum severity over several months.

What Is Still Uncertain About Guaifenesin

A key research limitation is that findings were mixed across various measured outcomes in the overall evidence base. Additionally, the sample sizes were modest in some original studies, and the research often relied on subjective symptom scales rather than objective biomarkers, contributing to a lower certainty of findings in some areas. For long-term usage, data are still emerging, and long-term effects are not fully established with the same certainty as data from short-term placebo-controlled trials. Subgroup findings are uncertain, as the results apply only to the populations studied.

Key Studies & References Guaifenesin Drug Information: Uses, Dosage, Side Effects (NIH MedlinePlus)

Frequently Asked Questions (FAQ)

Common questions about Guaifenesin (FAQ)


Q: What is the difference between Guaifenesin and Dextromethorphan?

A: Guaifenesin and Dextromethorphan have different primary actions described in official documents. Guaifenesin is classified as an expectorant, meaning its purpose is to thin and loosen mucus, which helps to make a cough more productive. Dextromethorphan, which is often included in combination cold products, is an antitussive, or cough suppressant, that acts to quiet the cough reflex itself.


Q: Does Guaifenesin help clear up a stuffy nose or congestion?

A: According to the official product information, Guaifenesin is primarily indicated to relieve chest congestion by affecting the mucus in the bronchial airways. It works specifically to thin phlegm in the lungs, but it is not typically indicated as a main ingredient for clearing a stuffy nose (nasal congestion).


Q: How quickly does Guaifenesin usually start to work?

A: Regulatory reviews of its pharmacokinetic profile indicate that the expectorant effects of Guaifenesin are typically observed approximately 30 minutes after taking the oral dose.


Q: Can Guaifenesin be used by people with high blood pressure?

A: Regulatory documents indicate that single-ingredient Guaifenesin does not typically affect blood pressure, unlike certain other cold ingredients. However, combination products containing decongestants often carry warnings that they may be restricted for use by individuals with hypertension.


Q: Is it safe to take Guaifenesin if I have diabetes?

A: Single-ingredient Guaifenesin has no known adverse effects on blood sugar control. However, some liquid formulations may contain sugar. For individuals with diabetes, verifying the inactive ingredients or selecting a sugar-free option is necessary.


Q: Does Guaifenesin make you drowsy or sleepy?

A: Official regulatory documents list side effects that may affect alertness, including dizziness and drowsiness. These effects are generally considered common when using Guaifenesin.


Q: Is it possible to become dependent on Guaifenesin if used often?

A: Regulatory information for single-ingredient Guaifenesin indicates a low potential for dependence. Potential for abuse or dependence is more frequently reported in association with certain combination products that contain other active ingredients.


Q: What happens if I forget to take a dose of Guaifenesin?

A: Regulatory information from patient leaflets typically describes the procedure if a dose is missed: the missed dose is generally skipped, and the regular dosing schedule is resumed. It is specified that a double dose should not be taken to compensate for a missed one.


Q: Why does Guaifenesin sometimes make me feel dehydrated?

A: Guaifenesin's mechanism of action involves drawing water into the respiratory secretions to thin the mucus. Because the drug draws water into the mucus, regulatory guidelines emphasize that each dose must be taken with a full glass of water, and insufficient fluid intake may contribute to feelings of dehydration.


Q: What is the connection between Guaifenesin and kidney stones?

A: Kidney stone formation (nephrolithiasis) has been reported in post-marketing surveillance and case reports. This association is often noted particularly in the ingestion of large amounts or misuse of Guaifenesin-containing products.


Q: Has there been research on Guaifenesin for fibromyalgia?

A: Guaifenesin is not approved by the FDA or other major regulatory bodies for the treatment of fibromyalgia. The official indications for this drug are limited to the relief of acute cough and chest congestion. Research into its off-label use for fibromyalgia has been limited and provided mixed results.


Q: Does Guaifenesin contain alcohol or sugar?

A: The presence of alcohol or sugar depends entirely on the specific product formulation. While many liquid Guaifenesin products are explicitly labeled as sugar-free or alcohol-free, the presence of these substances is product-specific. Verification of the inactive ingredients on the product label is necessary.


Q: How do I know if Guaifenesin is actually working for my cough?

A: According to the official treatment goal, Guaifenesin is working when your cough shifts to being more productive. This means a patient may be able to clear phlegm or thick mucus from the chest more easily, and the sputum may feel less thick or sticky.


Q: Does Guaifenesin treat the cause of the cough, or just the symptom?

A: Guaifenesin is officially classified as a symptomatic treatment. Its indication is for the temporary relief of symptoms like cough and chest congestion associated with the common cold or other minor respiratory irritations. It does not treat the underlying cause of the illness.


Q: Can older adults use Guaifenesin safely?

A: Single-ingredient Guaifenesin is generally considered to be well-tolerated for short-term use in older adults. However, official labeling notes that combination cold products carry specific warnings, as ingredients in these formulations may increase risks such as confusion or cardiovascular effects in older adults.


Q: What is the maximum duration of time Guaifenesin should be used?

A: Regulatory documents specify that for the self-treatment of an acute cough, use must be stopped, and medical reassessment is necessary if the cough lasts more than 7 days, returns, or is accompanied by other serious symptoms.


Q: Is Guaifenesin used for asthma or bronchitis symptoms?

A: Official labels include a warning that individuals who have a persistent cough (such as occurs with asthma or chronic bronchitis) are advised to seek professional guidance before using this medication. It is not approved for self-treatment of these specific chronic diseases.


Q: What are the restrictions on driving or operating machinery while using Guaifenesin?

A: Because side effects such as dizziness and drowsiness are reported, regulatory documents warn that tasks requiring full mental alertness, such as driving or operating heavy machinery, may be affected.


Q: Why is Guaifenesin often combined with other medications in cold formulas?

A: Guaifenesin is frequently combined with other active ingredients, such as decongestants or cough suppressants, to allow a single product to address multiple symptoms of a cold or flu concurrently. This provides a broader range of temporary relief from symptoms.


Q: Is Guaifenesin the same as the medication known by the brand name Robitussin?

A: Guaifenesin is the active ingredient found in a variety of cough and cold preparations. It is present in certain formulations sold under the Robitussin brand name, often in combination with other ingredients like Dextromethorphan or a decongestant.

How should Guaifenesin be stored and disposed of?

How to Store and Dispose of Guaifenesin

Guaifenesin must be stored according to regulatory labeling to maintain its stability and effectiveness. The mandated storage condition is Controlled Room Temperature, defined as a range between 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C.


Storage Constraints and Handling

The product must be protected from light and tablets must be protected from moisture. The labeling instructs to keep the container tightly closed and to Do not refrigerate or expose the medication to excessive heat. A critical safety instruction is to Keep out of the reach and sight of children.


Disposal Instructions

Expired or unused guaifenesin must be disposed of in accordance with applicable laws and regulations. Official guidance specifies that the medicine should not be thrown into household trash or wastewater. Patients are instructed to ask their pharmacist for guidance on appropriate disposal procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Guaifenesin found in:

A-Z Index: